Active Biotech and NeoTX announced that the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (naptumomab, ANYARA) in combination with AstraZeneca’s checkpoint inhibitor IMFINZI® (durvalumab) for the treatment of advanced or metastatic solid tumors. The study aims to establish the maximum tolerated dose in the dose-escalation Phase 1b study before advancing to a Phase 2 cohort expansion study. This open-label, multicenter, dose-finding Phase 1b trial will enroll patients with previously treated advanced or metastatic tumors. Patients will be treated with a combination of naptumomab and durvalumab.